Bachem stock gains support from 2025 results and 2026 guidance
Published on 07/27/2026 at 09:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bachem Holding AG (ISIN CH0012530207) stock stays anchored by 2025 revenue of CHF 605.4 million, which rose 13.9% year on year, while EBITDA reached CHF 149.8 million and the EBITDA margin improved to 24.8% in the same year.
According to the Bachem investor relations page, the group also guided for 2026 revenue growth of around 10% and an EBITDA margin of around 28% in constant currencies. That combination gives investors a clear comparison point after 2025, when the margin was 24.8% and revenue growth was 13.9%.
2025 revenue up 13.9%
The 2025 revenue figure of CHF 605.4 million matters because it came with a 13.9% increase from the prior year, showing that Bachem kept growing while lifting profitability. EBITDA of CHF 149.8 million in 2025 also supports the idea that the company ended the year with a firmer operating base than in 2024.
For a Swiss specialty chemicals name with exposure to peptide manufacturing, the margin trajectory is often the most important signal, and Bachem’s 24.8% EBITDA margin in 2025 was still below the 2026 target of around 28%. The gap is not dramatic, but it is measurable and therefore useful for tracking execution.
2026 margin target at 28%
Bachem’s 2026 guidance points to a year in which the company aims for around 10% revenue growth and an EBITDA margin of around 28% in constant currencies. That is a narrower but still meaningful improvement path after the 2025 margin of 24.8%, especially because the company is comparing itself against a higher revenue base of CHF 605.4 million.
The investor relevance lies in the mix: revenue growth of 13.9% in 2025, EBITDA of CHF 149.8 million, and a 2026 margin target of around 28% create a simple framework for judging whether the operational model is still scaling. If the company delivers closer to the upper end of that margin target, the market will likely focus less on sales alone and more on operating leverage.
Bachem 2025 results and 2026 outlook
Revenue, EBITDA and margin guidance show the current operating path for the Swiss peptide specialist.
Peptides remain the core
Bachem's business remains centered on peptides and related manufacturing services, which is the product base that turns the 2025 and 2026 numbers into a practical growth story. The point for investors is not the product category itself but whether the company can translate that specialization into a higher EBITDA margin than the 24.8% reported for 2025.
The relevance of the segment becomes clearer when placed beside the guidance: around 10% revenue growth in 2026 suggests continued demand, while the move toward an around 28% EBITDA margin suggests better operating leverage rather than pure volume expansion.
Price depends on execution
The share price line is omitted because no verified live quote is available in the present source set, but the market frame still centers on the 2025 revenue of CHF 605.4 million, the 2025 EBITDA of CHF 149.8 million and the 2026 margin target of around 28%. Those three figures are enough to define the next earnings test for Bachem stock.
As of 27 July 2026, the Swiss group therefore reads as a margin story as much as a growth story, with 2025 providing the base and 2026 offering the comparison point.
Company facts
Bachem Holding AG
- Company: Bachem Holding AG
- ISIN: CH0012530207
- Ticker: SIX: BANB
- Trading venue: SIX Swiss Exchange
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: Swiss small and mid cap universe
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
